Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B97409de54b01ecfce6910b5aa1d33bf3> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B97409de54b01ecfce6910b5aa1d33bf3 NCIT_P378 "NCI" @default.
- B97409de54b01ecfce6910b5aa1d33bf3 type Axiom @default.
- B97409de54b01ecfce6910b5aa1d33bf3 annotatedProperty IAO_0000115 @default.
- B97409de54b01ecfce6910b5aa1d33bf3 annotatedSource NCIT_C127934 @default.
- B97409de54b01ecfce6910b5aa1d33bf3 annotatedTarget "A microparticle combining two immune-modifying components derived from the bacterium Propionibacterium acnes, a bacterial cell wall component that is rich in muramyl dipeptide (MDP) and single-stranded bacteria-derived DNA fragments, with potential immunomodulating and immunoadjuvant activities. Upon administration of MIS416, this agent localizes in and is taken up mainly by the liver, thereby forming a liver depot. MIS416 is then taken up by immune cells, such as monocytes and dendritic cells (DCs), where MDP and the bacterial DNA target and bind to the cytosolic innate pattern recognition receptors (PRRs) nucleotide-binding oligomerization domain-containing protein 2 (NOD2), and toll-like receptor 9 (TLR9), respectively. The simultaneous binding and activation of both NOD2 and TLR9, leads to activation of both NOD2 and TLR9 signaling. This stimulates the innate immune system, induces secretion of cytokines, particularly interferon (IFN), and modulates the activation of various immune cells. In the presence of tumor-associated antigens (TAAs), through simultaneous administration of a TAA-based vaccine, MIS416 modulates T-cell subsets and enhances the cytotoxic T lymphocyte (CTL)-mediated immune response against TAAs, resulting in an increased anti-tumor immune response. The combination of NOD2 and TLR9 agonists in MIS416 appears to activate different signaling pathways as compared to the administration of NOD2 and TLR9 agonists alone." @default.